Skip to main content
. 2021 Jan 21;8:616972. doi: 10.3389/fcell.2020.616972

Figure 3.

Figure 3

Evaluation of prognosis model based on m6A regulators. (A–C) Univariate Cox regression analyses of m6A risk score and clinicopathologic factors in TCGA training cohort, TCGA validation cohort, and independent validation cohort. (D–G) Difference in distribution of m6A risk score of different tumor stages, tumor grades, metastasis status, and lymph node metastasis status in whole TCGA cohort. m6A, N6-methyladenosine; TCGA, The Cancer Genome Atlas.